Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

SAN FRANCISCO, September 28, 2025 — A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone ...

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

Add Yahoo as a preferred source to see more of our stories on Google. Men whose prostate cancer returns after surgery or radiation therapy may finally have a new treatment that helps them live longer.

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...